OPDP says website for weight-loss drug misleads

The FDA's Office of Prescription Drug Promotion said in a note to Citius and Akrimax that their website for weight-loss drug Suprenza omits material information, such as risk factors for certain patients and the patient population for which the drug is indicated. The OPDP also said the use of the word "lean" in the ad misleads consumers into thinking they will become slim or slender if they take the drug, but leanness was not a primary endpoint in clinical trials.

View Full Article in:

Medical Marketing & Media · Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC
Director, Health Services Analytics
Avalere Health
Washington, DC
Director/Vice President. Health Actuary
Avalere Health
Washington, DC
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD